SynCore Biotechnology Co.,Ltd (TPEX:4192)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
21.15
+0.60 (2.92%)
Jun 18, 2026, 1:33 PM CST
Market Cap743.73M -38.3%
Revenue (ttm)27.78M +14.1%
Net Income-45.07M
EPS-1.28
Shares Out 35.16M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume15,000
Open20.55
Previous Close20.55
Day's Range20.30 - 21.15
52-Week Range19.00 - 29.65
Beta0.31
AnalystsHold
Price Target363.07 (+1,616.64%)
Earnings DateAug 11, 2026

About TPEX:4192

SynCore Biotechnology Co.,Ltd, engages in development and sale of healthy food, medicine inspection, and biotechnology service in Taiwan. The company is involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer; and SB02, an anti-cancer NCE, which is in preclinical research for use in the treatment of stomach cancer. It also offers SB03-Veregen, an ointment for the treatment of patients with external genital and perianal warts EGW; and SB04, ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 40
Stock Exchange Taipei Exchange
Ticker Symbol 4192
Full Company Profile

Financial Performance

In 2025, TPEX:4192's revenue was 27.04 million, an increase of 15.88% compared to the previous year's 23.34 million. Losses were -45.76 million, -15.71% less than in 2024.

Financial Statements